Cue Biopharma grants RSUs and PSUs to legal chief

Ray Sumita reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Ray Sumita reported acquisition or exercise transactions in this Form 4 filing.

Cue Biopharma, Inc. granted Chief Legal Compliance Officer and Corporate Secretary Sumita Ray a total of 109,178 shares tied to equity awards on July 9, 2026. The awards comprise 54,589 restricted stock units (RSUs) vesting in equal quarterly installments over 48 months and 54,589 performance stock units (PSUs) that vest in three tranches only if stock-price targets of $33.00, $38.50 and $44.00 are each maintained for five consecutive trading days by 24 months from grant, otherwise the PSUs are forfeited.

Insider Trade Summary

Grant/Award: 109,178 shares

Grant/Award 2 txns

Insider Ray Sumita

Role Chief Legal Compliance Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F2	54,589	$0.00	$0.00
Grant/Award	Common Stock F1	54,589	$0.00	$0.00

Holdings After Transaction: Common Stock — 54,589 contracts (Direct); Common Stock — 109,178 shares (Direct)

Footnotes (2)

1. F1. Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.
2. F2. Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

Key Figures

RSU grant size: 54,589 shares PSU grant size: 54,589 shares Shares owned after transaction: 109,178 shares +5 more

8 metrics

RSU grant size 54,589 shares Restricted stock units granted to Sumita Ray on July 9, 2026

PSU grant size 54,589 shares Performance stock units granted to Sumita Ray on July 9, 2026

Shares owned after transaction 109,178 shares Direct ownership by Sumita Ray following the grants

RSU vesting period 48 months RSUs vest in equal quarterly installments from the grant date

First PSU stock-price hurdle $33.00 Closing price per share required for first PSU tranche vesting

Second PSU stock-price hurdle $38.50 Closing price per share required for second PSU tranche vesting

Third PSU stock-price hurdle $44.00 Closing price per share required for third PSU tranche vesting

PSU performance window 24 months Period from grant during which stock-price targets must be met before forfeiture

Key Terms

restricted stock units ("RSUs"), performance stock units ("PSUs"), closing price per share, trading days, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents that grant of restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

performance stock units ("PSUs") financial

"Represents the grant of performance stock units ("PSUs")."

closing price per share financial

"eligible to vest based the achievement of a closing price per share of $33.00"

trading days financial

"in each case for a period of five consecutive trading days."

Trading days are the specific days when a stock exchange is open and buying and selling of securities can occur, excluding weekends and exchange-declared holidays. Investors use trading days to measure performance, calculate settlement deadlines and time-sensitive events—think of them as the business hours calendar for markets, where returns, volumes and deadlines are counted only on days the market is operating.

forfeited and cancelled without consideration financial

"the PSUs shall automatically be forfeited and cancelled without consideration."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cue Biopharma (CUE) report for Sumita Ray?

Cue Biopharma reported that Sumita Ray, its Chief Legal Compliance Officer, received equity awards totaling 109,178 shares. These include RSUs vesting quarterly over 48 months and PSUs vesting only upon achieving specified stock-price hurdles within 24 months.

How many RSUs did Sumita Ray receive from Cue Biopharma (CUE)?

Sumita Ray received a grant of 54,589 restricted stock units (RSUs). These RSUs vest in equal quarterly installments over a 48‑month period from the grant date, conditioned on her continued service with Cue Biopharma.

What performance conditions apply to Sumita Ray’s PSUs at Cue Biopharma (CUE)?

The 54,589 PSUs are split into three tranches that may vest if Cue Biopharma’s stock closes at $33.00, $38.50, and $44.00 for five consecutive trading days. If these targets are not met within 24 months, the PSUs are forfeited.

What is Sumita Ray’s Cue Biopharma (CUE) share ownership after these grants?

Following the reported grants, Sumita Ray holds 109,178 shares of Cue Biopharma common stock directly. This figure reflects her position after the July 9, 2026 equity awards were recorded.

Did Sumita Ray pay any purchase price for the Cue Biopharma (CUE) awards?

The reported RSU and PSU grants to Sumita Ray list a transaction price per share of $0.00. These appear as compensation-related equity awards rather than open‑market purchases of Cue Biopharma stock.

Over what timeframe can Cue Biopharma (CUE) PSUs granted to Sumita Ray vest?

The PSUs can vest if the stock-price targets are achieved within 24 months from the grant date. If the closing-price conditions are not met in that period, all unvested PSUs are automatically forfeited without consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 07:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ray Sumita

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Legal Compliance Officer		Corporate Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		54,589(1)	A	$0	109,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	(2)	07/09/2026		A		54,589		(2)	(2)	Common Stock	54,589	$0	54,589	D

Explanation of Responses:

1. Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.

2. Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.

	/s/ Sumita Ray	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)